Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
Shots:
- Roche divulges results from three P-III studies of Tecentriq (atezolizumab) clinical development program in TNBC at the ESMO Virtual Congress 2020. The P-III IMpassion031 assessing Tecentriq + CT vs PBO + CT demonstrated improvement in pathological complete response (pCR: 57.6% vs 41.1%) in early TNBC patients
- The P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel vs PBO + nab-paclitaxel- as a 1L treatment for patients with m-TNBC. Results: increment in 7.5mos. in median OS- no new safety concerns were identified with longer follow-up
- Lastly- the company presented P-III IMpassion131 study assessing Tecentriq + paclitaxel vs PBO + paclitaxel- as a 1L treatment for patients with m-TNBC. The study did not meet its 1EPs of PFS in the PD-L1+ population- OS data showed a negative trend
Ref: Roche | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com